NEW YORK, Dec. 30, 2020 /PRNewswire-PRWeb/ -- Quantum Media Group, LLC today announced its coverage initiative on INmune Bio, a biotechnology company focused on modulating components of the innate immune system to treat cancers and chronic neurological diseases.
Quantum's research paper details the paradigm shift in Alzheimer's research and treatment strategies in development, rejecting the approach that the pharmaceutical industry and academia at large has focused on for the past few decades.
The paper further outlines how INmune Bio's XPro1595, an sTNF inhibitor, is particularly promising for Alzheimer's treatment, targeting neuroinflammation. Furthermore, Quantum believes that INmune shares could be significantly undervalued based on data supporting XPro1595's mechanism of action and XPro1595's market potential.
Quantum believes that INmune Bio's XPro1595 is potentially a best-in-class Alzheimer's drug, and further believes that the upcoming clinical trial readout will be encouraging.
The detailed report is available here: http://www.quantum-corp.com/equity-research
Meredith Egeland, Quantum Media Group, +1 (917) 680-8765, [email protected]
SOURCE Quantum Media Group